A Phase 2 interventional study of SHR3680 and SHR3162 in Prostate Cancer and Castration-resistant Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing rezvilutamide in Prostatic Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. rezvilutamide · Prostatic Neoplasms.
Among the 18 studies testing rezvilutamide in Prostatic Neoplasms, this one is the 15th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →10 of the 18 studies testing rezvilutamide in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75 · Men only
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18+ · Men only
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 40+ · Men only
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+ · Men only
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75 · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4
First in 2016; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 98 across the 18 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 7 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 14 open now, 17 under way, 4 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 25th largest by enrollment, is one of 2 that started in 2019, is one of 5 in phase 2, and was the 5th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Prostatic Neoplasms studies by the year they started, since 2016.
6 of the studies testing rezvilutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241416Phase 3Jiangsu HengRui Medicine Co., Ltd.A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | 2027-03 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT07444983Fujian Medical University Union HospitalRezvilutamide for High-Risk Prostate Cancer After Surgery | 2027-02-11 |
| NCT05753566The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolRezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | 2027-03 |
| NCT07711314The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAdjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy | 2027-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 18 studies testing rezvilutamide in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 31 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.
This is a multicenter, randomized , double-blind Phase II trial and the aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With Abiraterone and Docetaxel whether the patient's overall survival (OS) is superior to placebo. The Stage I part is a dose-escalation and -expansion study. Approximately 18\~24 patients in Stage I will receive fixed-dose of orally SHR3680 and only one of two dose levels of orally SHR3162. The Primary endpoints of the Stage I are incidence of adverse events(AE) and recommended phase 2 dose(RP2D). The Stage II part is a randomized , double-blind study. Approximately 90\~120 patients in Stage II will receive SHR3162 combined with SHR3680, in which one fixed-dose levels of SHR3162 will be selected based on the result of the Stage I.The Primary endpoint of the Stage II is overall survival(OS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SHR3680 combined with SHR3162 orally
Drug: SHR3680 · Drug: SHR3162
Participants will receive SHR3680 combined with SHR3162(Placebo) orally
Drug: SHR3680 · Drug: SHR3162(Placebo)
Participants will receive SHR3680(Placebo) combined with SHR3162(Placebo) orally
Drug: SHR3680(Placebo) · Drug: SHR3162(Placebo)
Adverse Event(AE)
The type, frequency, severity, timing, seriousness, and relationship to study therapy
Time frame: Approximately 70 months
Overall Survival(OS)
Time from randomisation to death due to any cause
Time frame: Approximately 70 months
Time to prostate specific antigen (PSA) progression
Time from randomisation to the first time of PSA progression according to the criterion of PCGW3
Time frame: Approximately 70 months
Radiographic Progression Free Survival(rPFS)
Time from randomisation to radiologically confirmed progressive disease or death due to any cause
Time frame: Approximately 70 months
Objective response rate (ORR)
The percentage of patients with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
Time frame: Approximately 70 months
Time to skeletal-related events
Time from randomisation to the first occurrence of a skeletal-related event. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery.
Time frame: Approximately 70 months
PSA response rate
After the continuous therapy from randomisation to the end of the 12 weeks, the percentage of patients whose levels of PSA decreased by more than 50% compared with baseline.
Time frame: Approximately 70 months
Area Under the Curve (AUC)
The single dose and multiple dose PK will be calculated as data permits including AUC
Time frame: Approximately 12 months
Maximum Observed Plasma Concentration (Cmax)
The single-dose and multiple dose PK will be calculated as data permits including Cmax
Time frame: Approximately 12 months
Minimum Observed Plasma Concentration (Cmin)
The single-dose and multiple dose PK will be calculated as data permits including Cmin
Time frame: Approximately 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2019 to primary completion in Aug 2021, 28 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rezvilutamide · Fluzoparib
Jiangsu HengRui Medicine Co., Ltd. →